Rowe et al. (Nature, 2012) established that pregnancy imprints maternal FOXP3+ regulatory T cells (Tregs) with fetal-antigen specificity: these cells persist after delivery, rapidly re-expand in a subsequent pregnancy, and protect against fetal loss. The open problem is the durability, maintenance mechanism, human counterpart, and safe therapeutic exploitation of this antigen-specific regulatory memory. Specifically unresolved are: the quantitative long-term kinetics of fetal-specific Treg persistence after parturition and the determinants of its waning or maintenance across extended inter-pregnancy intervals; whether persistence reflects bona fide antigen-independent memory, tonic stimulation by fetal microchimeric cells retained in the mother, or a defined interplay of both; how retained fetal-specific Tregs differ from naive Tregs in molecular program, T-cell receptor repertoire and antigen affinity, and tissue localization; whether women possess analogous antigen-specific regulatory memory and whether its waning causally explains the partner-specific and inter-birth-interval epidemiology of pre-eclampsia and fetal growth restriction; and whether this memory can be deliberately boosted to sustain tolerance without compromising maternal host defence.

Background

During pregnancy the maternal immune system must tolerate a fetus that expresses paternally inherited antigens the mother lacks — a naturally occurring semi-allogeneic graft. A central mechanism of this tolerance is a population of CD4+ regulatory T cells (Tregs), identified by expression of the transcription factor FOXP3, which suppress other immune cells rather than attacking foreign antigen themselves. Before 2012, Kahn and Baltimore had shown that pregnancy elicits a fetal-antigen-specific maternal Treg response, but the extreme rarity of antigen-specific cells made it impossible to determine which cells expanded, where they came from, or whether they persisted after delivery.

Rowe et al. (2012) used tetramer-based enrichment — a flow-cytometry method in which fluorescent complexes of peptide and major histocompatibility complex (MHC, the molecule that displays peptide fragments to T cells) bind the T-cell receptor of cells with a given specificity, allowing rare endogenous antigen-specific T cells to be counted — to track maternal CD4 cells specific for a defined fetal antigen across genetically disparate (allogeneic) murine pregnancies. They showed that pregnancy selectively accumulates fetal-specific FOXP3+ Tregs; that these cells persist at elevated frequency after delivery and rapidly re-accumulate in a subsequent pregnancy with the same male; that the accelerated secondary expansion derives almost entirely from proliferation of cells retained from the first pregnancy; and that secondary pregnancies become more resilient to partial Treg depletion, measured with DEREG mice (a diphtheria-toxin-receptor transgenic strain in which FOXP3+ cells can be conditionally ablated). In the authors' words, pregnancy imprints regulatory memory that sustains anergy — antigen-specific unresponsiveness — to fetal antigen. Crucially, the same group had shown that the Treg expansion sustaining pregnancy also weakens maternal defence against prenatal bacterial pathogens (Rowe et al. 2011), so any therapeutic exploitation of this memory must respect a tolerance-versus-host-defence trade-off.

The paper left a bundle of linked questions open, later sharpened by the authors themselves (Kinder et al. 2014; Rosenblum, Way and Abbas 2016): how long the fetal-specific Treg population persists numerically and functionally after parturition, and what determines its waning or maintenance over extended inter-pregnancy intervals; whether persistence is bona fide antigen-independent memory or is sustained by fetal-cell microchimerism (long-term retention of small numbers of genetically fetal cells in maternal tissues); how retained fetal-specific Tregs differ molecularly and functionally from naive Tregs; whether women possess analogous antigen-specific regulatory memory; and whether such memory can be deliberately boosted without compromising host defence.

Human epidemiology makes these questions concrete. Compared with first pregnancies, later pregnancies with the same partner carry markedly lower risks of pre-eclampsia (a hypertensive pregnancy disorder associated with inadequate maternal immune adaptation) and fetal growth restriction, but this protection is lost with a change of partner (Trupin et al. 1996) and decays as the interval between births lengthens, approaching the risk of first pregnancies after about ten years (Skjærven et al. 2002) — a time course consistent with, though not proof of, waning antigen-specific regulatory memory. Subsequent work has confirmed the murine phenomenon and begun to explain its maintenance and mechanisms (Shao et al. 2023; Thiele et al. 2025; Nguyen et al. 2026) and to probe human fetal-specific tolerance (Morgan et al. 2025; Tsuda et al. 2018), yet the long-term kinetics, the human antigen-specific Treg memory, its epidemiological causality, and safe therapeutic exploitation all remain unresolved.

Problem Statement

The problem, posed by Rowe et al. (2012) and subsequently sharpened by the same group and the field (Kinder et al. 2014; Rosenblum, Way and Abbas 2016; Shao et al. 2023), still open in its core, is to establish the durability, maintenance mechanism, and exploitable character of pregnancy-imprinted regulatory memory to fetal antigen, comprising five linked questions that jointly define one objective: (1) Long-term kinetics: quantify how long fetal-antigen-specific FOXP3+ regulatory T cells persist numerically and functionally after parturition (delivery) — in particular beyond the roughly 100-day postpartum window mapped in mice — and identify the factors that determine whether this memory wanes or is maintained across extended inter-pregnancy intervals. (2) Maintenance mechanism: establish whether persistence reflects bona fide self-renewing regulatory memory, continuing antigenic stimulation by fetal microchimeric cells retained in maternal tissues, or a defined interplay of both, and how this maintenance is simultaneously partner-/antigen-specific yet resilient to intervening pregnancies with different paternity. (3) Mechanistic definition: determine how retained fetal-specific FOXP3+ cells differ from naive regulatory T cells — in molecular programs, T-cell receptor repertoire and antigen affinity, and tissue localization (including whether they form tissue-resident populations in the uterus or decidua) — sufficiently to identify, track, and purify them. (4) Human counterpart: determine whether analogous fetal/paternal-antigen-specific regulatory memory exists in healthy women, how durable it is across inter-pregnancy intervals, and whether its presence or waning causally explains the epidemiological pattern in which parity with the same partner protects against pre-eclampsia and fetal growth restriction while partner change or long inter-birth intervals restore the risk of a first pregnancy. (5) Exploitation: determine whether this regulatory memory can be deliberately boosted or otherwise manipulated to sustain protective tolerance in subsequent or high-risk pregnancies without compromising maternal host defence, which pregnancy-associated Treg expansion is known to weaken. Completion standard: these five questions are jointly necessary; a solution must give a direct answer to each of (1)–(5), and resolving only a strict subset of them — for example the murine long-term kinetics and maintenance mechanism, (1)–(2), alone — leaves the task unresolved. Each part must also be answered in its own form: (1) a quantitative persistence result, whether measured or modelled, together with the factors that govern waning or maintenance; (2) positive evidence discriminating among the listed maintenance sources rather than exclusion of one by another; (3) a characterization concrete enough to identify, track and purify the retained cells; (4) antigen-specific evidence in women together with an explicit assessment of the direction and strength of the causal link to the epidemiology; (5) a concrete manipulation together with evidence that protective tolerance is sustained without loss of host defence. An assertion that a part is unproven, or an answer to one part that rests solely on another, does not resolve it.

References

  1. Rowe JH, Ertelt JM, Xin L, Way SS. Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. Nature 490, 102–106 (2012). DOI: 10.1038/nature11462. https://doi.org/10.1038/nature11462
  2. Kahn DA, Baltimore D. Pregnancy induces a fetal antigen-specific maternal T regulatory cell response that contributes to tolerance. Proc. Natl Acad. Sci. USA 107, 9299–9304 (2010). DOI: 10.1073/pnas.1003909107. https://doi.org/10.1073/pnas.1003909107
  3. Rowe JH, Ertelt JM, Aguilera MN, Farrar MA, Way SS. Foxp3+ regulatory T cell expansion required for sustaining pregnancy compromises host defense against prenatal bacterial pathogens. Cell Host Microbe 10, 54–64 (2011). DOI: 10.1016/j.chom.2011.06.005. https://doi.org/10.1016/j.chom.2011.06.005
  4. Kinder JM, Jiang TT, Clark DR, Chaturvedi V, Xin L, Ertelt JM, Way SS. Pregnancy-induced maternal regulatory T cells, bona fide memory or maintenance by antigenic reminder from fetal cell microchimerism? Chimerism 5, 16–19 (2014). DOI: 10.4161/chim.28241. https://doi.org/10.4161/chim.28241
  5. Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. Nat. Rev. Immunol. 16, 90–101 (2016). DOI: 10.1038/nri.2015.1. https://doi.org/10.1038/nri.2015.1
  6. Shao TY, Kinder JM, Harper G, Pham G, Peng Y, Liu J, Gregory EJ, Sherman BE, Wu Y, Iten AE, Hu YC, Russi AE, Erickson JJ, Miller-Handley H, Way SS. Reproductive outcomes after pregnancy-induced displacement of preexisting microchimeric cells. Science 381, 1324–1330 (2023). DOI: 10.1126/science.adf9325. https://doi.org/10.1126/science.adf9325
  7. Thiele K, Urbschat C, Riquelme JIA, Ahrendt LS, Wöhrle R, Schepanski S, Eckert JJ, Becht E, Qi M, Alawi M, Becker M, Gagliani N, Mittrücker HW, Diemert A, Arck PC. Pregnancy-acquired memory CD4+ regulatory T cells improve pregnancy outcome in mice. Nat. Commun. 16, 6522 (2025). DOI: 10.1038/s41467-025-61572-w. https://doi.org/10.1038/s41467-025-61572-w
  8. Nguyen NNM, Brady AE, Russi A, Pham G, Li B, Turner LH, Kotliar M, Barski A, Sun X, Way SS. Maternal Krüppel-like factor 2 (KLF2)+ CD4 T cells promote fertility and fetal tolerance. Proc. Natl Acad. Sci. USA 123, e2519393123 (2026). DOI: 10.1073/pnas.2519393123. https://doi.org/10.1073/pnas.2519393123
  9. Morgan JC, Hynes GE, Pollard JM, Andrade MS, Jeong JC, Chong AS. Hyporesponsive fetus-specific T cell responses in multiparous human pregnancy. Front. Immunol. 16, 1634430 (2025). DOI: 10.3389/fimmu.2025.1634430. https://doi.org/10.3389/fimmu.2025.1634430
  10. Koenig ZT, Eswar S, Tsuda S, Schuldt N, Chougnet CA, Forde B, Andorf S, Tilburgs T. Decidual CD4 effector memory and resident memory T cells respond to cord blood allo-antigens. Am. J. Reprod. Immunol. 95, e70213 (2026). DOI: 10.1111/aji.70213. https://doi.org/10.1111/aji.70213
  11. Tsuda S, Zhang X, Hamana H, Shima T, Ushijima A, Tsuda K, Muraguchi A, Kishi H, Saito S. Clonally expanded decidual effector regulatory T cells increase in late gestation of normal pregnancy, but not in preeclampsia, in humans. Front. Immunol. 9, 1934 (2018). DOI: 10.3389/fimmu.2018.01934. https://doi.org/10.3389/fimmu.2018.01934
  12. Chen Z, Zhou X, Qu H, Zhang X, Kwak-Kim J, Wang W. Characteristics and functions of memory regulatory T cells in normal pregnancy cycle and pregnancy complications. J. Reprod. Immunol. 163, 104235 (2024). DOI: 10.1016/j.jri.2024.104235. https://doi.org/10.1016/j.jri.2024.104235
  13. Wang W, Zhou X, Zhang Y, Chen Z, Huang J, Zhang X, Kwak-Kim J. The characteristics of antigenic specificity of memory regulatory T cells in women with unexplained recurrent pregnancy loss. J. Reprod. Immunol. 154, 103694 (2022). DOI: 10.1016/j.jri.2022.103694. https://doi.org/10.1016/j.jri.2022.103694
  14. Zhang YJ, Shen L, Zhang T, Muyayalo KP, Luo J, Mor G, Liao AH. Immunologic memory in pregnancy: focusing on memory regulatory T cells. Int. J. Biol. Sci. 18, 2406–2418 (2022). DOI: 10.7150/ijbs.70629. https://doi.org/10.7150/ijbs.70629
  15. Chen Z, Zhang Y, Kwak-Kim J, Wang W. Memory regulatory T cells in pregnancy. Front. Immunol. 14, 1209706 (2023). DOI: 10.3389/fimmu.2023.1209706. https://doi.org/10.3389/fimmu.2023.1209706
  16. Trupin LS, Simon LP, Eskenazi B. Change in paternity: a risk factor for preeclampsia in multiparas. Epidemiology 7, 240–244 (1996). DOI: 10.1097/00001648-199605000-00004. https://doi.org/10.1097/00001648-199605000-00004
  17. Skjærven R, Wilcox AJ, Lie RT. The interval between pregnancies and the risk of preeclampsia. N. Engl. J. Med. 346, 33–38 (2002). DOI: 10.1056/NEJMoa011379. https://doi.org/10.1056/NEJMoa011379
  18. Foyle KL, Chin PY, Merkwirth C, Wilson J, Hosking SL, Green ES, Chong MY, Zhang B, Moldenhauer LM, Ferguson GD, Morris GP, Karras JG, Care AS, Robertson SA. IL-2 complexed with anti-IL-2 antibody expands the maternal T-regulatory cell pool and alleviates fetal loss in abortion-prone mice. Am. J. Pathol. 194, 2128–2149 (2024). DOI: 10.1016/j.ajpath.2024.07.012. https://doi.org/10.1016/j.ajpath.2024.07.012
  19. Mekinian A, Abisror N, Mcavoy C, Ribet C, Lorenzon R, Vicaut E, Rosenzwajg M, Klatzmann D. Low-dose interleukin-2 for recurrent early pregnancy loss: a proof-of-concept study. Preprint (2025). DOI: 10.1101/2025.06.13.25328550. https://doi.org/10.1101/2025.06.13.25328550